CCNU in the treatment of canine epitheliotropic lymphoma

Laurel E. Williams, Kenneth M. Rassnick, Helen T. Power, Susan E. Lana, Kirsten E. Morrison-Collister, Katherine S Hansen, Jeffrey L. Johnson

Research output: Contribution to journalArticle

63 Scopus citations

Abstract

This retrospective study examined the use of CCNU (1-[2-chloroethyl]3- cyclohexyl-1-nitrosurea) in 36 dogs with epitheliotropic lymphoma. Thirty-one (86%) dogs had the cutaneous form of disease, and 5 (14%) dogs had the oral form of disease. Nineteen (51%) dogs were treated with other chemotherapeutic agents before receiving CCNU. All dogs had detectable disease at the time CCNU therapy was initiated. Dogs received a median starting CCNU dosage of 70 mg/m 2 (range, 50-100 mg/m2). The median number of treatments administered was 3 (range, 1-12 treatments). After the initial treatment, the CCNU dosage was adjusted in 9 of 26 (35%) dogs in which CCNU was continued: 7 had dosage reductions, and 2 had dosage escalations. Twenty-eight of 36 (78%) dogs had a measurable response to CCNU for a median duration of 106 days (95% confidence interval [CI], 75-182). Six dogs (17%) had a complete response, including 5 dogs with the cutaneous form and 1 dog with the oral form. Twenty-two dogs (61%) had a partial response, including 20 dogs with the cutaneous form and 2 dogs with the oral form, for a median duration of 88 days (95% CI, 62-170). Toxicoses after CCNU chemotherapy included myelosuppression in up to 29% of the dogs, gastrointestinal signs in up to 22% of the dogs, and liver enzyme activity increases in up to 86% of the dogs. This study demonstrates that CCNU chemotherapy can be considered a reasonable option for the treatment of canine epitheliotropic lymphoma in dogs.

Original languageEnglish (US)
Pages (from-to)136-143
Number of pages8
JournalJournal of Veterinary Internal Medicine
Volume20
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Keywords

  • Dog
  • Medicine chemotherapy
  • Mycosis fungoides

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'CCNU in the treatment of canine epitheliotropic lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Williams, L. E., Rassnick, K. M., Power, H. T., Lana, S. E., Morrison-Collister, K. E., Hansen, K. S., & Johnson, J. L. (2006). CCNU in the treatment of canine epitheliotropic lymphoma. Journal of Veterinary Internal Medicine, 20(1), 136-143. https://doi.org/10.1892/0891-6640(2006)20[136:CITTOC]2.0.CO;2